Vaccine after CAR-T therapy for multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests whether a personalized vaccine (DC/MM fusion) given after standard CAR-T cell therapy can help prevent the cancer from coming back. It is for people with multiple myeloma that has returned or not responded to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are getting or have gotten CAR-T cell therapy as part of your regular treatment.
- You are 18 years or older.
- Your cancer cells (plasma cells) make up at least 20% of your bone marrow.
- Your liver and kidneys are working well enough (based on blood tests).
- You must use birth control during the study and for 6 months after.
- You cannot have other serious infections (like HIV, hepatitis) or unstable heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called CAR-T cell therapy for people with multiple myeloma that has come back or not responded to other treatments. The treatment uses your own immune cells, modified in a lab to attack the cancer, and may be an option after a stem cell transplant has not worked.
This early trial tests a new CAR-T cell treatment targeting three proteins (CD19, CD22, and BCMA) on myeloma cells. It's for people whose myeloma came back or didn't respond to at least three prior treatments.
This trial tests a new treatment that combines a stem cell transplant with special immune cells (called CAR-T cells) to fight multiple myeloma. The goal is to see if this combined approach helps people with newly diagnosed myeloma achieve better control of their disease.
This Phase 1/2 study tests a personalized CAR-T cell treatment that targets a protein called BCMA on myeloma cells. It’s designed for people with multiple myeloma who have already tried several other treatments and still have measurable disease.
This trial tests a special type of immune therapy called CAR T cells, which are made from your own blood cells and then given back to you to fight the cancer. It is for people with multiple myeloma who have not gotten better with other treatments or whose cancer has come back.
This study looks at how well vaccines work in people with multiple myeloma or certain lymphomas after they receive CAR-T cell therapy. It aims to help doctors understand the best way to revaccinate patients to protect against preventable diseases.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.